ライフサイエンスコーパス: efalizumab

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 vide evidence for the mechanism of action of efalizumab.

2 and after treatment with an LFA-1 inhibitor, efalizumab.

3 jects with psoriasis to receive subcutaneous efalizumab (1 or 2 mg per kilogram of body weight per we

4 o to receive 12 weekly doses of subcutaneous efalizumab, 1 mg/kg (n = 369), or placebo equivalent (n

5 Efalizumab, a humanized monoclonal antibody, binds to th

6 Efalizumab and natalizumab administration is associated

7 ntly, the monoclonal antibodies natalizumab, efalizumab, and rituximab--used for the treatment of mul

8 Efalizumab (anti-CD11a) interferes with LFA-1/ICAM-1 bin

9 Treatment of psoriasis with efalizumab (anti-CD11a, Raptiva) strongly reduces infilt

10 77 percent of those who continued to receive efalizumab, as compared with 20 percent of those who wer

11 After the discontinuation of efalizumab at week 24, an improvement of 50 percent or m

12 e of anergy, Ca(+2) release is intact during efalizumab binding.

13 The effectiveness of one of these agents, efalizumab, did not achieve statistical significance in

14 antileukocyte functional antigen-1 antibody efalizumab (EFA), which permit long-term islet allograft

15 h severe atopic dermatitis were treated with efalizumab for 84 days, and peripheral blood mononuclear

16 data from the humanized anti-LFA-1 antibody efalizumab have provided proof-of-concept for LFA-1 as a

17 lonal antibodies rituximab, natalizumab, and efalizumab have received regulatory approval in the USA

18 Efalizumab is a humanized monoclonal CD11a antibody appr

19 Efalizumab is an mAb directed against CD11a, a molecule

20 on into tissue is the major pathway by which efalizumab leads to improvement in cutaneous inflammatio

21 Our data suggest that efalizumab may induce a unique type of T-cell hyporespon

22 This study characterizes the effects of efalizumab on T-cell activation responses and expression

23 ved an additional 12 weeks of treatment with efalizumab or placebo.

24 ent of the subjects who had received 1 mg of efalizumab per kilogram per week and 28 percent of those

25 28 percent of those who had received 2 mg of efalizumab per kilogram per week, as compared with 5 per

26 roval of two new anti-adhesion therapeutics: efalizumab (Raptiva) targeting LFA-1 for the treatment o

27 ple sclerosis and Crohn's disease) or LFA-1 (efalizumab; Raptiva for severe forms of plaque psoriasis

28 In this 12-week study, efalizumab resulted in significant improvements in clini

29 Efalizumab therapy resulted in significant improvements

30 that T-cell responses may be reduced during efalizumab therapy, but are reversible after ceasing efa

31 Twenty-seven percent of efalizumab-treated patients achieved PASI-75 vs 4% of th

32 Efalizumab-treated patients exhibited significantly grea

33 Efalizumab-treated patients experienced significantly gr

34 Efalizumab-treated subjects had greater improvement than

35 Among the efalizumab-treated subjects who had an improvement of 75

36 Efalizumab treatment led to decreases in CD11a mean fluo

37 llel-group study of 12 weeks of subcutaneous efalizumab treatment of patients with moderate psoriasis

38 In summary, efalizumab treatment resulted in (i) decreases in CD11a

39 During efalizumab treatment, both primary and secondary antibod

40 ab therapy, but are reversible after ceasing efalizumab treatment.

41 Efalizumab was safe and well tolerated, with primarily m

42 Efalizumab was well tolerated, and adverse events were g

43 al vaccination 6 weeks after withdrawal from efalizumab were not affected.

44 kade, without tolerance to the antigen after efalizumab withdrawal.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。